PharmaMar to supply Jazz with drug product under $1bn deal

By Nick Taylor

- Last updated on GMT

(Image: Getty/Robert Daly)
(Image: Getty/Robert Daly)

Related tags PharmaMar Jazz Pharmaceuticals

PharmaMar set to supply Jazz Pharmaceuticals with cancer drug from two sites under terms of $1bn deal.

Late last year, Jazz revealed it had agreed to pay PharmaMar $200m (€180m) upfront for exclusive US rights to lurbinectedin, a late-phase treatment for small cell lung cancer (SCLC). Jazz also committed up to $800m in milestones to secure the rights to the drug, which is designed to induce cell death by inhibiting activated transcription and inducing DNA double-strand breaks.

PharmaMar began 2019 by holding a conference call with investors to discuss the deal. Analysts used the call to question PharmaMar about the production of lurbinectedin and who will be responsible for what tasks.

Responding to an analyst question, Luis Mora, managing director of PharmaMar’s oncology business, said, “We will sell the active ingredient to Jazz Pharmaceuticals and then Jazz Pharmaceuticals will commercialize​.”

Spain’s PharmaMar will carry out production activities at two facilities that Mora thinks have capacity to support commercialization of lurbinectedin.

PharmaMar looks to the sea for inspiration, leading it to base its one approved drug Yondelis (trabectedin) on a molecule produced by the sea squirt. However, lurbinectedin is made through a synthetic process.

The establishment of a process that starts with fermentation and runs through 18 synthesis steps has enabled PharmaMar to cost-effectively produce the drug to good manufacturing practice (GMP) standards.

Having done that, PharmaMar thinks it is well set to supply lurbinectedin in the quantities needed by Jazz.

Mora said, “We have sufficient raw materials, suppliers, et cetera, in order to be sure there’s not any issue about the commercial supply. The cost of the drug is not disclosed, obviously, but is highly cost efficient​.”

How much lurbinectedin PharmaMar will need to make to meet demand is unclear at this stage. The Spanish drug developer filed for US Food and Drug Administration (FDA) approval late last year, putting it on track to gain clearance to sell lurbinectedin some time in 2020.

If approved, lurbinectedin could become the first new chemical entity authorized by the FDA in the treatment of SCLC in more than 20 years.

Since the approval of Hycamtin (topotecan) in the 1990s, Bristol-Myers Squibb and Merck have won approval for their checkpoint inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab), respectively, in SCLC. However, those drugs were already on the market in other indications at the time of the SCLC approvals and are only authorized in third-line settings. Lurbinectedin could come to market as a second-line treatment.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us